Literature DB >> 23044775

Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks.

Che-Kai Tsao, William K Oh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23044775     DOI： 10.1038/nrclinonc.2012.181

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

Review 1.  Overcoming castration resistance in prostate cancer.

Authors:  Che-Kai Tsao; Alexander C Small; Matthew D Galsky; William K Oh
Journal:  Curr Opin Urol       Date:  2012-05       Impact factor: 2.309

2.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

3.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

4.  Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.

Authors:  Charles J Ryan; Eric P Elkin; Eric J Small; Janeen Duchane; Peter Carroll
Journal:  Urol Oncol       Date:  2006 Sep-Oct       Impact factor: 3.498

5.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

Review 7.  Side effects of corticosteroid therapy.

Authors:  A L Buchman
Journal:  J Clin Gastroenterol       Date:  2001-10       Impact factor: 3.062

8.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728
  8 in total
  1 in total

Review 1.  Trial Watch: DNA vaccines for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-04-01       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.